Opthea Limited

As biosimilars flood into the wet age-related macular degeneration (AMD) market, they are reshaping the competitive landscape that was long dominated by anti-vascular endothelial growth factor (VEGF)

Special purpose acquisition corporations did not have a very successful run in the last SPAC wave to hit the life science sector, but a new round of the vehicles that provide companies an alternative

4D Molecular Therapeutics Inc. ’s share price nearly doubled today after a mid-stage trial of its wet age-related macular degeneration gene therapy showed that patients could do without injections of

Third Harmonic Bio Inc. could be the first biopharmaceutical company to launch an initial public offering in the US since the end of July and deliver the first biopharma IPO to raise more than $100m